Showing 2951-2960 of 3315 results for "".
- New Licensing Agreement Accelerates the Development of IACTA Pharmaceuticals’ Novel Dry Eye Disease and Allergic Conjunctivitis Treatments in China and Southeast Asiahttps://modernod.com/news/new-licensing-agreement-accelerates-the-development-of-iacta-pharmaceuticals-novel-dry-eye-disease-and-allergic-conjunctivitis-treatments-in-china-and-southeast-asia/2478088/IACTA Pharmaceuticals and Zhaoke Ophthalmology Pharmaceutical (ZKO), a Hong Kong-based pharmaceutical company, announced they have entered into a definitive license agreement on the licensing of two of the company’s products, IC 265 for dry eye and IC 270 fo
- Pfizer, BioNTech Begin Phase 2/3 Coronavirus Vaccine Studyhttps://modernod.com/news/pfizer-biontech-pick-bnt162b2-to-advance-into-phase-2-3-coronavirus-vaccine-study/2478084/Pfizer and partner BioNTech said they have decided to advance the nucleoside-modified mRNA vaccine candidate BNT162b2 into phase 2/3 testing. The vaccine, to be trialed at the 30-mcg dose as part of a two-dose regimen, encodes for an optimized SARS-CoV-2 full-length spike glycoprotein, which the
- Algorithm Compares Risk of Cancelled Ophthalmology Appointments Against COVID-19https://modernod.com/news/algorithm-compares-risk-of-cancelled-ophthalmology-appointments-against-covid-19/2478075/The COVID-19 pandemic has forced many ophthalmologists across the US to cancel potentially necessary eye examinations with patients since March. A team, led by Nikhil K. Bommakanti, MD, W.K. Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan, developed a f
- Maculopathy Tied to Pentosan Polysulfate Sodium May Worsen After Drug Cessationhttps://modernod.com/news/maculopathy-tied-to-pentosan-polysulfate-sodium-may-worsen-after-drug-cessation/2478071/Pentosan polysulfate sodium (PPS)-associated maculopathy may continue for at least 10 years after drug cessation and in some cases may pose a threat to central vision, according to a case report, Reuters reported. The condition 
- Moderna Loses US Patent Challenge That Could Affect COVID-19 Vaccinehttps://modernod.com/news/moderna-loses-us-patent-challenge-that-could-affect-covid-19-vaccine/2478072/Shares in Moderna fell as much as 10% Thursday after the company failed in an attempt to invalidate a US patent on vaccine technology held by Arbutus Biopharma. SVB Leerink analyst Mani Foroohar suggested the decision by an administrative court run by the US Patent and Trademark Office opens the
- Hadley Launches New Website For Those Facing Vision Losshttps://modernod.com/news/hadley-launches-new-website-for-those-facing-vision-loss/2478068/In 1920, William Hadley, a Chicago area high school teacher who lost his sight at the age of 55, revolutionized the way adults facing vision loss would learn to read again when he created his Braille by Mail system. One hundre
- GenSight Biologics Reports Final REALITY Study Confirms Poor Spontaneous Recovery for LHON Patients with ND4 mutationhttps://modernod.com/news/gensight-biologics-reports-final-reality-study-confirms-poor-spontaneous-recovery-for-lhon-patients-with-nd4-mutation/2478050/GenSight Biologics reported results from the final analysis of the REALITY natural history study, which reaffirm the poor prognosis for the vast majority of Leber Hereditary Optic Neuropathy (LHON) patients with vision loss due to a mutated ND4mitochondrial gene. “The REALITY findings bols
- A Potential New Approach to Combat Drug Resistance in Age-Related Macular Degenerationhttps://modernod.com/news/a-potential-new-approach-to-combat-drug-resistance-in-age-related-macular-degeneration/2478031/An international team of researchers led by Baylor College of Medicine and Houston Methodist has discovered a strategy that can potentially address a major challenge to the current treatment for choroidal neovascularization (CNV), according to a university news release. Anti-vascular endot
- Tarsus Pharmaceuticals Announces Appointment of New COO and CFOhttps://modernod.com/news/tarsus-pharmaceuticals-announces-appointment-of-new-coo-and-cfo/2478029/Tarsus Pharmaceuticals announced the appointment of two pharmaceutical veterans to its executive leadership team: Sesha Neervannan, PhD, to the position of Chief Operating Officer (COO), and Leo Greenstein to the position of Chief Financial Officer (CFO). As part of its leadership, Sesha and Leo
- COVID-19 Has Flipped the Physician Job Search to a Seller’s Market, Recruiters Sayhttps://modernod.com/news/covid-19-has-flipped-the-physician-job-search-to-a-sellers-market-recruiters-say/2478020/Job opportunities for doctors have dried up quite a bit in wake of the COVID-19 pandemic, at least in the short term, according to an annual report from physician search firm Merritt Hawkins, according to a FierceHealthcare